1292258-15-1

Basic information

• Product Name: N-(3-fluoro-4-{6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yloxy}phenyl)-2-trifluoromethoxybenzenesulfonamide
• CAS NO: 1292258-15-1
• Molecular Weight: 664.678
• Mol File: 1292258-15-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(3-fluoro-4-{6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yloxy}phenyl)-2-trifluoromethoxybenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-fluoro-4-{6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yloxy}phenyl)-2-trifluoromethoxybenzenesulfonamide(1292258-15-1)
• EPA Substance Registry System: N-(3-fluoro-4-{6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yloxy}phenyl)-2-trifluoromethoxybenzenesulfonamide(1292258-15-1)

Safety Data

• Hazardous Substances Data: 1292258-15-1(Hazardous Substances Data)

Upstream product

• 960299-66-5 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline 
• 479690-08-9 1-(2-fluoro-4-nitrophenyl)-6-hydroxy-7-methoxy-quinoline 
• 286371-49-1 7-(benzyloxy)-4-chloro-6-methoxyquinoline 
• 960299-67-6 3-fluoro-4-{6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yloxy}phenylamine 
• 103008-51-1 2-(trifluoromethoxy)benzenesulfonyl chloride 

Relevant articles and documents

Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors

The overexpression of AXL kinase has been described in many types of cancer. Due to its role in proliferation, survival, migration, and resistance, AXL represents a promising target in the treatment of the disease. In this study we present a novel compound family that successfully targets the AXL kinase. Through optimization and detailed SAR studies we developed low nanomolar inhibitors, and after further biological characterization we identified a potent AXL kinase inhibitor with favorable pharmacokinetic profile. The antitumor activity was determined in xenograft models, and the lead compounds reduced the tumor size by 40% with no observed toxicity as well as lung metastasis formation by 66% when compared to vehicle control.

QUINOLINYLOXYPHENYLSULFONAMIDES

The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or after-treatment of hyperproliferative disorders, such as cancer, tumors and particularly cancer metastases.